Surgery Partners Q2 revenue up 2.7% to $848.9M; reaffirms FY2026 guidance

Surgery Partners, Inc.

Q2 revenue $848.9M, up 2.7% YoY; same-facility revenue +5.0%, cases +0.3%.
Net loss attributable to SGRY $15.0M; Adjusted EBITDA $125.2M vs $129.0M in Q2 2025.
FY2026 guidance reaffirmed: revenue $3.35-3.45B, Adjusted EBITDA at least $530M, excluding pending Idaho Falls divestiture.
Pending Idaho Falls, Idaho facility divestiture subject to physician member and governing board approvals; expected to improve cash conversion and deleverage.
Cash $216.7M, $617.8M revolver capacity; net debt/EBITDA ~4.4x; Q2 operating cash flow $59.3M vs $81.3M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.